Abstract
Non small cell lung cancer (NSCLC) is a lethal disease with poor prognosis. The main percentage of NSCLC patients are diagnosed to have an advanced disease. Standard treatment, such as chemotherapy and radiotherapy, has apparently reached a plateau of effectiveness in improving survival of advanced NSCLC patients. Hence, considerable efforts have started to be made in order to identify novel targets for new biological agents which may safely and effectively be administered to advanced NSCLC patients. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptors play an essential role in tumour proliferation. Approaches targeting EGFR and VEGF include monoclonal antibodies (mAbs) and small molecules inhibiting the corresponding receptor- tyrosine kinase activity. Erlotinib is a small molecule inhibitor of EGFR tyrosine-kinase which has brought significant improvements in median survival, quality of life and related symptoms, in an unselected population of advanced NSCLC patients in the second- or third-line setting. Bevacizumab, an anti-VEGF recombinant humanized mAb, is the first targeted agent which, when combined with chemotherapy, reported superior efficacy versus chemotherapy alone in the treatment of advanced NSCLC. ZD6474, a small molecule targeting VEGF tyrosine-kinase activity, showing early evidence of antitumour activity and the excellent toxicity profile, seems to be a promising agent for the treatment of advanced NSCLC. This review shows the latest and the future developments of erlotinib, bevacizumab and ZD6474 in the treatment of advanced NSCLC patients.
Current Drug Discovery Technologies
Title: Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer
Volume: 6 Issue: 2
Author(s): Antonio Rossi, Paolo Maione, Giuseppe Colantuoni, Carmine Ferrara, Emanuela Rossi, Ciro Guerriero, Dario Nicolella, Marzia Falanga, Giovanni Palazzolo and Cesare Gridelli
Affiliation:
Keywords: NSCLC, EGFR, erlotinib, VEGF, bevacizumab, ZD6474
Abstract: Non small cell lung cancer (NSCLC) is a lethal disease with poor prognosis. The main percentage of NSCLC patients are diagnosed to have an advanced disease. Standard treatment, such as chemotherapy and radiotherapy, has apparently reached a plateau of effectiveness in improving survival of advanced NSCLC patients. Hence, considerable efforts have started to be made in order to identify novel targets for new biological agents which may safely and effectively be administered to advanced NSCLC patients. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptors play an essential role in tumour proliferation. Approaches targeting EGFR and VEGF include monoclonal antibodies (mAbs) and small molecules inhibiting the corresponding receptor- tyrosine kinase activity. Erlotinib is a small molecule inhibitor of EGFR tyrosine-kinase which has brought significant improvements in median survival, quality of life and related symptoms, in an unselected population of advanced NSCLC patients in the second- or third-line setting. Bevacizumab, an anti-VEGF recombinant humanized mAb, is the first targeted agent which, when combined with chemotherapy, reported superior efficacy versus chemotherapy alone in the treatment of advanced NSCLC. ZD6474, a small molecule targeting VEGF tyrosine-kinase activity, showing early evidence of antitumour activity and the excellent toxicity profile, seems to be a promising agent for the treatment of advanced NSCLC. This review shows the latest and the future developments of erlotinib, bevacizumab and ZD6474 in the treatment of advanced NSCLC patients.
Export Options
About this article
Cite this article as:
Rossi Antonio, Maione Paolo, Colantuoni Giuseppe, Ferrara Carmine, Rossi Emanuela, Guerriero Ciro, Nicolella Dario, Falanga Marzia, Palazzolo Giovanni and Gridelli Cesare, Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer, Current Drug Discovery Technologies 2009; 6 (2) . https://dx.doi.org/10.2174/157016309788488339
DOI https://dx.doi.org/10.2174/157016309788488339 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design A Functional Proteomic Approach to the Identification and Characterization of Protein Composition in Wheat Leaf
Current Proteomics Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Adult Neural Stem Cell Therapy: Expansion In Vitro, Tracking In Vivo and Clinical Transplantation
Current Drug Targets Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design Synthesis of Pyrophosphate-Containing Compounds that Stimulate VγVδ2 T Cells: Application to Cancer Immunotherapy
Medicinal Chemistry Therapy of Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia
Current Pharmaceutical Design Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Editorial [Hot Topic: Anti-Lipogenesis as a Novel Strategy for Cancer Therapy (Guest Editors: Jianghua Liu and Deliang Cao)]
Recent Patents on Anti-Cancer Drug Discovery A Review of Recent Advancements in Anti-tubercular Molecular Hybrids
Current Medicinal Chemistry Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression
Current Molecular Medicine Editorial [ Hot Topic: Therapeutic Potential of Peptide Motifs - Part III (Executive Editor: Jean-Claude Herve) ]
Current Pharmaceutical Design T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Pulmonary and Nasal Anti-Inflammatory and Anti-Allergy Inhalation Aerosol Delivery Systems
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Use of Transgenic Mouse Models to Understand the Origins of Familial Pulmonary Fibrosis
Current Pharmaceutical Biotechnology Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets